The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.

The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.

INTRODUCTION: Capsular group B meningococcal disease is a leading cause of childhood meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in > 30% of survivors. A vaccine, four component meningococcal group B ( 4CMenB ), designed with the aim to induce broad coverage ag...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Rollier, C, Dold, C, Marsay, L, Sadarangani, M, Pollard, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	Taylor and Francis 2014

Ähnliche Einträge

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component.
von: Sheerin, D, et al.
Veröffentlicht: (2019)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
von: Dold, C, et al.
Veröffentlicht: (2023)

Four component meningococcal capsular Group B vaccine in preterm infants.
von: Sadarangani, M, et al.
Veröffentlicht: (2017)

Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation
von: Rollier, CS, et al.
Veröffentlicht: (2022)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
von: Kesanopoulos, K, et al.
Veröffentlicht: (2018)

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
von: Davis, K, et al.
Veröffentlicht: (2021)

Exploiting real-time genomic surveillance data to assess 4CMenB meningococcal vaccine performance in Scotland, 2015 to 2022
von: Rodrigues, CMC, et al.
Veröffentlicht: (2023)

Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine
von: Cotugno, N, et al.
Veröffentlicht: (2024)

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
von: Sadarangani, M, et al.
Veröffentlicht: (2017)

B Part Of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine program on carriage of Neisseria meningitidis
von: Marshall, H, et al.
Veröffentlicht: (2019)

The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study
von: Davis, K, et al.
Veröffentlicht: (2019)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
von: Snape, M, et al.
Veröffentlicht: (2015)

Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis
von: Awanye, A, et al.
Veröffentlicht: (2019)

Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland
von: Mulhall, R, et al.
Veröffentlicht: (2018)

Of mice and MenB: assessing the immune mechanisms underlying meningococcal capsular group B vaccines in mice
von: Sheerin, D
Veröffentlicht: (2019)

Serogroup B meningococcal vaccines-an unfinished story.
von: Sadarangani, M, et al.
Veröffentlicht: (2010)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
von: Sheerin, D, et al.
Veröffentlicht: (2022)

B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents
von: Marshall, HS, et al.
Veröffentlicht: (2018)

The next chapter for group B meningococcal vaccines
von: Wang, N, et al.
Veröffentlicht: (2017)

Group B meningococcal vaccine science and policy
von: Drysdale, SB, et al.
Veröffentlicht: (2015)

Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010–2016
von: Rodrigues, C, et al.
Veröffentlicht: (2018)

Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial
von: Rollier, CS, et al.
Veröffentlicht: (2022)

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
von: Carr, J, et al.
Veröffentlicht: (2020)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
von: Lewis, S, et al.
Veröffentlicht: (2009)

Group B meningococcal vaccine: Recommendations for UK use
von: Pollard, A, et al.
Veröffentlicht: (2014)

Group B meningococcal vaccine: recommendations for UK use.
von: Pollard, A, et al.
Veröffentlicht: (2014)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
von: O'Connor, D, et al.
Veröffentlicht: (2020)

Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison
von: Channon-Wells, SW, et al.
Veröffentlicht: (2022)

Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine
von: Weissmueller, N, et al.
Veröffentlicht: (2017)

Emerging clinical experience with vaccines against group B meningococcal disease
von: Wilkins, A, et al.
Veröffentlicht: (2017)

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
von: Valente Pinto, M, et al.
Veröffentlicht: (2020)

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
von: Marsay, L, et al.
Veröffentlicht: (2015)

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity
von: Marsay, L, et al.
Veröffentlicht: (2022)

Global epidemiology of meningococcal disease and vaccine efficacy
von: Pollard, A
Veröffentlicht: (2004)

Global epidemiology of meningococcal disease and vaccine efficacy.
von: Pollard, A
Veröffentlicht: (2004)

An OMV vaccine derived from a capsular group B meningococcus with constitutive FetA expression: preclinical evaluation of immunogenicity and toxicity
von: Norheim, G, et al.
Veröffentlicht: (2015)

Safety of meningococcal group B vaccination in hospitalised premature infants
von: Kent, A, et al.
Veröffentlicht: (2018)

Meningococcal vaccines.
von: Collins, C, et al.
Veröffentlicht: (2002)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
von: Pace, D, et al.
Veröffentlicht: (2016)

Meningococcal meningitis presenting postinfant group B meningococcal immunisation
von: So, N, et al.
Veröffentlicht: (2018)